Resolve Therapeutics Investors
Our Company

Investors

Resolve has been supported since its' inception in 2010 by several leading venture capital firms, including:

New Science Ventures
(NSV) is a New York-based venture capital firm which invests in both early and late stage companies using novel scientific approaches to address significant unmet needs and create order of magnitude improvements in performance. NSV manages over $150 million and has invested in more than 20 companies located in the US, Europe, India and China in the life sciences and information technology sectors. www.newscienceventures.com

Easton Capital
Easton Capital manages approximately $200 million on behalf of a number of significant institutional investors in its three funds, Easton Capital Partners, L.P., Easton Hunt Capital Partners, L.P. and Easton Hunt New York L.P. Easton makes investments ranging in size from $2 million to $7.5 million and has strategic co-investment relationships with many of its institutional investors which allow it to participate in larger initial and follow-on rounds of funding. Easton has offices in New York and Florida. www.eastoncapital.com

Washington Research Foundation
WRF Capital is the venture investment arm of the Washington Research Foundation, an independent organization founded in 1981 to support research and scholarship at Washington state research institutions. A leading early-stage investor, WRF Capital partners with entrepreneurs, investors, local universities, and research institutions to develop market-leading technology companies. Proceeds from investments are used to make financial gifts to Washington State research institutions to support scholarship and research. Examples of WRF Capital's life science companies include Accelerator, Alder Biopharmaceuticals, Amnis (acquired by EMD Millipore), Cardeas Pharma, Corus Pharma (acquired by Gilead Sciences), Ekos, GlobeImmune, HaloSource (LSE: HALO.L), Hyperion Therapeutics (NASDAQ: HPTX), Ikaria, Lumera (NasdaqNM: LMRA), Mirador Biomedical, Omeros (NASDAQ: OMER), Pathway Medical Technologies (acquired by MEDRAD), Targeted Growth, VLST, and Uptake Medical. www.wrfcapital.com